Jennifer Yuchen Shih, MD, MS
Although patients with invasive lobular carcinoma (ILC) are typically treated with the same therapeutic strategies as those with infiltrating ductal malignancies, ILC is emerging as a molecularly complex and distinct tumor type that suggests different approaches may be effective.
Table. Genomic Alterations in Invasive Lobular Cancer Subtypes3
ER indicates estrogen receptor.
“The genomic analyses show that invasive lobular cancers have more mutations in the PI3 kinase pathway—AKT foci, or the ERBB2/ERBB3,” said Shih. “These mutations are potential treatment targets in the future. There are investigations going on right now using AKT pathway inhibitors and other inhibitors that could potentially work better in this type of breast cancer than in other types for that reason.”